Lupin Limited (Lupin) has received final approval for its Paroxetin Extended Release Tablets USP, 12.5 mg, 25 mg and 37.5 mg from the United States Food and Drug Administration (FDA) to market a generic version of Apotex Technologies, Inc's Paxil CR® Tablets, 12.5 mg, 25 mg and 37.5 mg. Lupin shall commence promoting the product shortly.
Lupin's Paroxetin Extended Release Tablets USP, 12.5 mg, 25 mg and 37.5 mg are the AB rated generic equivalents of Apotex Technologies, Inc's Paxil CR® Tablets, 12.5 mg, 25 mg and 37.5 mg. It is indicated for the treatment of major depressive disorder, panic disorder, social anxiety disorder and premenstrual dysphoric disorder.
Paxil CR® Tablets had US sales of USD 127.7 million (IMS MAT September 2016).
Shares of LUPIN LTD. was last trading in BSE at Rs.1482.5 as compared to the previous close of Rs. 1461.8. The total number of shares traded during the day was 55277 in over 3583 trades.
The stock hit an intra day high of Rs. 1494 and intraday low of 1450.75. The net turnover during the day was Rs. 81810870.
Source: Lupin Receives FDA Approval for Generic Paxil CR® Tablets
No comments:
Post a Comment